Navigation Links
Collegium Pharmaceutical Announces Relocation to Massachusetts
Date:1/17/2013

CANTON, Mass., Jan. 17, 2013 /PRNewswire/ -- Collegium Pharmaceutical, Inc., a specialty pharmaceutical company focused on the development of innovative treatments for chronic pain, today announced the relocation of its corporate offices and laboratory facilities to Canton, Massachusetts from Cumberland, Rhode Island.

The Company's lead development program is Oxycodone DETERx® (COL-003), a tamper-resistant, extended-release oxycodone product utilizing its proprietary DETERx® technology. The Oxycodone DETERx® formulation was specifically designed to provide and preserve extended release of the active ingredient following the most common methods of product tampering employed by drug abusers (e.g., crushing, chewing, heating for IV injection, etc.). The product is currently in the final stage of clinical development and has been designated Fast Track Status by the FDA due to its potential to address the problem of prescription drug abuse, a major public health issue in the U.S.

Extended-release formulations of opioids (e.g., OxyContin®) are known to be attractive targets for non-medical use since they contain large doses of drug. Crushing these dosage forms can defeat the extended-release properties and result in immediate availability of the opioid, also known as "dose dumping." Crushed formulations are commonly self-administered by abusers orally, intranasally or by IV injection, resulting in a "high." Although marketed formulations carry labels warning against crushing and breaking, there are reports of legitimate pain patients crushing tablets to facilitate swallowing, a practice that significantly increases their risk of serious adverse events.

"We are pleased to have completed our relocation to Massachusetts. The new analytical and development labs will facilitate the completion
'/>"/>

SOURCE Collegium Pharmaceutical, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Collegium Pharmaceutical to Present at Piper Jaffrays 24th Annual Healthcare Conference
2. Report Presents a Framework for Successful New Oncology Product Launches in the Pharmaceutical Sector
3. Savient Pharmaceuticals to Hold First Quarter 2012 Financial Results Conference Call on Wednesday, May 9, 2012
4. Pharmaceutical Industry Service Company Awarded The UKs Most Prestigious Business Accolade in Recognition of Outstanding Achievement in International Trade
5. Auxilium Pharmaceuticals to Present at the Deutsche Bank 37th Annual Healthcare Conference
6. Simcere Pharmaceutical Group to Announce First Quarter 2012 Financial Results on Wednesday, May 9, 2012
7. Nouveau Life Pharmaceuticals (HRID) Contracts with U.S. Manufacturer to Produce New Female Supplement
8. Thomson Reuters Launches New Mobile Oncology Decision Support Solution for R&D Pharmaceutical Leaders
9. Amgen to Acquire Mustafa Nevzat, a Leading Privately Held Turkish Pharmaceutical Company
10. BioElectronics Survey Indicates a Five-Fold Superior Pain Relief Compared to OTC Pharmaceuticals
11. Icahn Issues Statement Regarding Amylin Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/20/2014)... , 20 de octubre de 2014 /PRNewswire/ ... el campo de la pulmonología intervencional, anunció hoy ... RENEW, casi 3 meses antes de lo programado. El ... exención de dispositivo de investigación (IDE) aprobada por ... el sistema de espiral de reducción de volumen ...
(Date:10/20/2014)... , Oct. 20, 2014  Luoxis Diagnostics, Inc., ... AMPE), today announced that its academic collaborators will ... research potential for its novel RedoxSYS Diagnostic System, ... in the body in response to injury or ... ORP as a clinical marker will be presented ...
(Date:10/20/2014)... Oct. 20, 2014 Valeritas, Inc., a leader ... patients with Type 2 diabetes, announced today that it ... Award. The award was presented October 16 th ... Columbus, Ohio . The Cardinal ... a variety of metrics specifically targeted at the importance ...
Breaking Medicine Technology:PneumRx concluye inscripción en prueba fundamental RENEW 2PneumRx concluye inscripción en prueba fundamental RENEW 3Luoxis to Highlight RedoxSYS at Two Upcoming Scientific Conferences 2Luoxis to Highlight RedoxSYS at Two Upcoming Scientific Conferences 3Luoxis to Highlight RedoxSYS at Two Upcoming Scientific Conferences 4Luoxis to Highlight RedoxSYS at Two Upcoming Scientific Conferences 5Valeritas Receives 2014 Cardinal Health Supply Chain Excellence Award 2Valeritas Receives 2014 Cardinal Health Supply Chain Excellence Award 3
... PARSIPPANY, N.J. , Jan. 14 As ... market, the company has announced the addition of three Vice ... these positions bring a deep knowledge of the spine and ... distribution networks in their respective areas.   , Randy ...
... , HORSHAM, Pa. , ... 3 clinical study comparing the efficacy and safety of STELARA™ ... severe plaque psoriasis appear today in The New England ... clinical response with both doses of STELARA than with etanercept ...
Cached Medicine Technology:Custom Spine Announces the Expansion of its Sales Management Team 2STELARA(TM) Shows Greater Efficacy Than Etanercept for Treatment of Moderate to Severe Plaque Psoriasis: Phase 3 Comparator Study Published in The New England Journal of Medicine 2STELARA(TM) Shows Greater Efficacy Than Etanercept for Treatment of Moderate to Severe Plaque Psoriasis: Phase 3 Comparator Study Published in The New England Journal of Medicine 3STELARA(TM) Shows Greater Efficacy Than Etanercept for Treatment of Moderate to Severe Plaque Psoriasis: Phase 3 Comparator Study Published in The New England Journal of Medicine 4STELARA(TM) Shows Greater Efficacy Than Etanercept for Treatment of Moderate to Severe Plaque Psoriasis: Phase 3 Comparator Study Published in The New England Journal of Medicine 5STELARA(TM) Shows Greater Efficacy Than Etanercept for Treatment of Moderate to Severe Plaque Psoriasis: Phase 3 Comparator Study Published in The New England Journal of Medicine 6STELARA(TM) Shows Greater Efficacy Than Etanercept for Treatment of Moderate to Severe Plaque Psoriasis: Phase 3 Comparator Study Published in The New England Journal of Medicine 7STELARA(TM) Shows Greater Efficacy Than Etanercept for Treatment of Moderate to Severe Plaque Psoriasis: Phase 3 Comparator Study Published in The New England Journal of Medicine 8STELARA(TM) Shows Greater Efficacy Than Etanercept for Treatment of Moderate to Severe Plaque Psoriasis: Phase 3 Comparator Study Published in The New England Journal of Medicine 9
(Date:10/22/2014)... News) -- Two sisters in high school have developed ... and Medha Krishen use electronic stethoscopes, which electronically amplify ... breathing patterns or heartbeats. Ilina, a senior at ... find a way to detect early lung damage in ... stethoscope, Ilina recorded one breath cycle each from 16 ...
(Date:10/22/2014)... Maureen Salamon HealthDay Reporter ... crucial part of conventional in vitro fertilization (IVF) -- the ... take place in a device inside the vagina, new research ... that the device, called an INVOcell, might sharply cut costs ... make the technology more accessible to those who don,t live ...
(Date:10/22/2014)... HealthDay Reporter , MONDAY, Oct. 20, 2014 (HealthDay ... for health workers treating Ebola patients, now requiring full body ... at all times. The U.S. Centers for Disease Control ... Dallas nurses contracted Ebola while caring for the first ... Duncan. Nina Pham is currently being treated for her infection ...
(Date:10/20/2014)... October 20, 2014 The newly updated ... source of thousands of facts, figures and forecasts on ... 68 medical sector forecast categories the Worldwide Medical ... regional and national views on the worldwide medical market ... The report gives you data for 2010-2019, covering each ...
(Date:10/20/2014)... Allegheny General Hospital’s (AGH) Cardiovascular Institute ... to repair a damaged mitral valve as the heart ... developed by Abbott Vascular , is designed to ... condition in which the heart’s mitral valve leaflets fail ... the heart’s left ventricle into the left atrium. The ...
Breaking Medicine News(10 mins):Health News:Teen Sisters Develop Ways to Measure Lung, Heart Damage 2Health News:Experimental Infertility Treatment Seems Effective, Cheaper 2Health News:Experimental Infertility Treatment Seems Effective, Cheaper 3Health News:Experimental Infertility Treatment Seems Effective, Cheaper 4Health News:CDC Tightens Rules on Caring for Ebola Patients 2Health News:CDC Tightens Rules on Caring for Ebola Patients 3Health News:Worldwide Medical Market Forecasts to 2019 a New Research Report Added to ReportsnReports.com 2Health News:Worldwide Medical Market Forecasts to 2019 a New Research Report Added to ReportsnReports.com 3Health News:Worldwide Medical Market Forecasts to 2019 a New Research Report Added to ReportsnReports.com 4Health News:Allegheny General Hospital Introduces New, Beating-Heart Procedure for Mitral Valve Repair 2Health News:Allegheny General Hospital Introduces New, Beating-Heart Procedure for Mitral Valve Repair 3
... ... Connecticut will present "Life of a Woman: Development from Pre-Teen to Menopause" during the ... Street in downtown Stamford, CT. , ... Norwalk, CT (PRWEB) May 1, 2010 -- Dr. Mark Leondires ...
... VA Despite their widespread use by parents and ... a warning by the FDA since 2008, and still ... infants and children. Conservative therapies, including nasal suctioning, humidification, ... of OTC cough/cold products in infants and children, according ...
... researchers and scientists from around the world will gather ... most prestigious gastroenterology meeting, from May 1 to May ... New Orleans, LA. DDW is the annual meeting of ... oldest GI society in the world. AGA researchers will ...
... frontal lobe damage, researchers find , FRIDAY, April 30 (HealthDay ... in people with damage to the frontal lobes of the ... of remorse and empathy are among the personality traits of ... the subject of debate. , In this study, Israeli researchers ...
... ... any athlete requiring therapy for fatigued or overused shoulder and elbows. , ... Dallas, TX (PRWEB) May 2, 2010 -- ... or overused shoulder and elbows. This great new product was named Best of Show at ...
... U.S. still fares worse than many other countries, CDC experts ... 2006, the latest year for which figures are available, about ... States, a 3 percent drop from 2005 and the lowest ... , Although the drop in infant mortality was significant, the ...
Cached Medicine News:Health News:Fertility Doctor to Speak at Fairfield County Women's Expo 2Health News:Fertility Doctor to Speak at Fairfield County Women's Expo 3Health News:Commentary suggests alternatives to routine use of OTC cold/cough meds in children 2Health News:AGA presents cutting-edge research during DDW 2Health News:AGA presents cutting-edge research during DDW 3Health News:AGA presents cutting-edge research during DDW 4Health News:Chilly-Billy Ice Compress - Arm Care for Athletes 2Health News:Chilly-Billy Ice Compress - Arm Care for Athletes 3Health News:U.S. Infant Deaths on the Decline 2Health News:U.S. Infant Deaths on the Decline 3
... provides optimized balance of pulse strength, pulse ... cleaning in the O.R. Unlike disposable plastic ... forged in die-cast metal and powered by ... The result is unparalleled performance in cleaning, ...
... 6000 lets you manually ... precise positioning. The superior ... immediate and exact positioning ... making it especially effective ...
... SP Surgical Table combines innovation and design ... up to 1,000 lbs. You can safely ... normal and reverse orientation and have virtually ... patients.,The Amsco 3085 SP Table offers the ...
... The hands play an important part ... traumatic impairments and rheumatic changes can cause ... developing of the finger-joint prostheses was to ... reproduce the natural function as nearly possible.,The ...
Medicine Products: